CLCS (Cell Source) Debt-to-Equity: -0.54 (As of Dec. 2024)

What is Cell Source Debt-to-Equity?

Cell Source CLCS -3.12% 35 Debt-to-Equity is -0.54 as of Dec. 2024. GuruFocus rates CLCS with a GF Score™ of 35/100.

Cell Source's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $10.07 Mil. Cell Source's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.00 Mil. Cell Source's Total Stockholders Equity for the quarter that ended in Dec. 2024 was $-18.54 Mil. Cell Source's debt to equity for the quarter that ended in Dec. 2024 was -0.54.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cell Source's Debt-to-Equity or its related term are showing as below:

CLCS's Debt-to-Equity is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.16
* Ranked among companies with meaningful Debt-to-Equity only.

Cell Source (OTCPK:CLCS) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cell Source Debt-to-Equity Related Terms

Cell Source Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Cell Source's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cell Source Debt-to-Equity Chart

Cell Source Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Equity

Get a 7-Day Free Trial

-0.61

-0.66

-0.63

-0.59

-0.54

Cell Source Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Equity	Get a 7-Day Free Trial															-0.59	-0.56	-0.56	-0.52	-0.54

CLCS vs EDSA, CTXR, ASBP: Debt-to-Equity Comparison

For the Biotechnology subindustry, Cell Source's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cell Source Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cell Source's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cell Source's Debt-to-Equity falls into.

Save Embed

35GF Score

Cell Source Inc CLCS

Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Cell Source Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cell Source's Debt to Equity Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.068	+	0)	/	-18.538
	=	-0.54

Cell Source's Debt to Equity Ratio for the quarter that ended in Dec. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.068	+	0)	/	-18.538
	=	-0.54

Frequently Asked Questions Learn more about Debt-to-Equity →

What does a Debt-to-Equity of -0.54 mean?

Cell Source (CLCS) has a Debt-to-Equity of -0.54 as of Dec. 2024. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cell Source and its competitors.

Is Cell Source's Debt-to-Equity too high?

Cell Source's current Debt-to-Equity is -0.54. Overall, Cell Source has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.

How does Cell Source's Debt-to-Equity compare to EDSA and CTXR?

Cell Source's Debt-to-Equity of -0.54 can be compared against companies in the Biotechnology industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Debt-to-Equity for a Biotechnology company?

The median Debt-to-Equity among Biotechnology companies is 0.16, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Debt-to-Equity mean?

A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Cell Source and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cell Source's current Debt-to-Equity is -0.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Cell Source stock overvalued right now?

Cell Source (CLCS) has a current Debt-to-Equity of -0.54. The current Debt-to-Equity is -0.54. Cell Source's overall GF Score™ is 35/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Debt-to-Equity calculated?

Debt-to-Equity is calculated from a company's financial statements. For Cell Source (CLCS), the current Debt-to-Equity is -0.54 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cell Source Business Description

Industry Healthcare Biotechnology

Comparable Companies EDSA CTXR ASBP CLRB ABP CASI SYBX LEXX THAR LGVN VRTX ASX:CSL REGN ALNY XKRX:207940 XBRU:ARGX XBRU:UCB ONC INSM XKRX:068270

Address 57 West 57th Street, Suite 400, New York, NY, USA, 10019

Website https://www.cell-source.com

Cell Source Inc is a biotechnology company focused on developing cell therapy treatments focused on immunotherapy. The company is involved with the development of proprietary immune system management technology. The company's subsidiary commercializes a suite of inventions relating to certain cancer treatments. The other products include Anti-rejection Veto Cell tolerance therapy for both matched and mismatched allogeneic bone marrow transplantations and Anti-rejection Veto Cell tolerance therapy for both matched as well as mismatched organ transplantation.

35GF Score

Get the complete analysis for CLCS

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.93

Price

View CLCS Analysis

See Debt-to-Equity data for all stocks →